Senior Research Analyst Mike Kuchenreuther recently spoke with Drug Store News about biosimilars and the challenges manufacturers face when they go through the approval process.

In order to be deemed interchangeable, the manufacturer must demonstrate the biosimilar is sufficiently similar to the reference product and is expected to produce the same clinical result.

Read the full story in the February issue of Drug Store News.